The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs

Covid19 Clinical Trial

Official title:

The Relationship Between Mild Covid-19 Infection in Pediatric Patients and Protection of Secondary Lymphoid Organs

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04646525
• Other study ID #: 2020/480
• Status: Recruiting
• Start date: October 1, 2020
• Est. completion date: February 1, 2021

Study information

• Verified date: November 2020
• Source: Selcuk University
• Contact: Selcen Celik
• Phone: +9033222443963
• Email: etikselcuk[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We aimed to find out whether the tonsils and nasal tissues of pediatric patients are the main factors that protects the children's immune system against COVID-19 infection.

Description:

Since it is known that the tonsil and adenoid tissues that are known as a secondary lymphoid organ, which form the first line of defense, are more active in childhood than adults, especially in the childhood age group, and since it has been scientifically shown that patients diagnosed with COVID-19 infection in the pediatric age group overcome this disease lightly than adults, we aimed to reveal whether the defined tonsil and adenoid tissues are the main factors that protect the children's immune system against COVID-19 infection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: February 1, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 16 Years

Eligibility

Inclusion Criteria:

• Patients with COVID-19 infection.
• Patients aged between 1-16 years
• Patients whose PCR test becomes negative

Exclusion Criteria:

• Patients with lymphoid tissue malignant disease
• Patients with known lung disease
• Patients with known systemic disease

Related Conditions & MeSH terms

• Adenoid Hypertrophy
• Adenoiditis
• Covid19
• Hypertrophy
• Immune Deficiency
• Immunologic Deficiency Syndromes
• Tonsil Hypertrophy
• Tonsillitis

Intervention

Diagnostic Test:
• Physical examination
Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.

Locations

Country	Name	City	State
Turkey	Selcuk University	Konya	Selcuklu

Sponsors (1)

Lead Sponsor	Collaborator
Selcuk University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Brodin P. Why is COVID-19 so mild in children? Acta Paediatr. 2020 Jun;109(6):1082-1083. doi: 10.1111/apa.15271. Epub 2020 Apr 15. — View Citation

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020 Jun;145(6). pii: e20200702. doi: 10.1542/peds.2020-0702. Epub 2020 Mar 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome of our study was the evaluation of pediatric patients diagnosed with COVID-19 and who had COVID-19 infection in terms of adenoid and tonsillar tissue hypertrophy and the presence of chronic or recurrent infection.	The structure of the tonsil and adenoid tissues will be examined by physical examination, and the presence of tonsil and adenoid hypertrophy, tonsillitis, and adenoiditis conditions will be identified. The severity of covid-19 will be determined according to the cases of patients with tonsil and adenoid tissue disorders, who are hospitalized in intensive care, have infiltration in the lungs, and receive oxygen support.	2020-2021